✦ LIBER ✦

Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma

✍ Scribed by Seiji Naito; Taiji Tsukamoto; Masaru Murai; Koichi Fukino; Hideyuki Akaza

Book ID: 110923758
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 411 KB
Volume: 108
Category: Article
ISSN: 1464-4096
DOI: 10.1111/j.1464-410x.2011.10281.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

7147 Efficacy and safety of long-term us

7147 Efficacy and safety of long-term use of sorafenib: final report of a phase II trial of sorafenib in Japanese patients with unresectable/metastatic renal cell carcinoma

✍ Akaza, H.; Naito, S.; Tsukamoto, T.; Murai, M.; Fukino, K. 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 65 KB

Randomized Phase II Trial of First-Line

Randomized Phase II Trial of First-Line Treatment With Sorafenib Versus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma

✍ Coplen, D.E. 📂 Article 📅 2009 🏛 Elsevier Science ⚖ 69 KB

A randomised, double-blind phase III stu

A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update

✍ Sternberg, Cora N.; Hawkins, Robert E.; Wagstaff, John; Salman, Pamela; Mardiak, 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 293 KB

Re: A Randomised, Double-Blind Phase III

Re: A Randomised, Double-Blind Phase III Study of Pazopanib in Patients with Advanced and/or Metastatic Renal Cell Carcinoma: Final Overall Survival Results and Safety Update

✍ Laguna, M. Pilar 📂 Article 📅 2013 🏛 Lippincott Williams and Wilkins 🌐 English ⚖ 55 KB

Improved tolerability and quality of lif

Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-α-2b : Results of a randomized phase II trial of low-dose versus intermediate-dose interferon-α-2b in patients with metastatic renal cell carcinoma

✍ Nizar M. Tannir; Lorenzo Cohen; Xuemei Wang; Peter Thall; Paul F. Mathew; Eric J 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 132 KB 👁 2 views

Subcutaneous interleukin-2 and interfero

Subcutaneous interleukin-2 and interferon α in the treatment of patients with metastatic renal cell carcinoma—Less efficacy compared with intravenous interleukin-2 and interferon α : Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie

✍ Alain Ravaud; Rémy Delva; Fréderic Gomez; Christine Chevreau; Jean-Yves Douillar 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB 👁 1 views

## Background: The main objective of this trial was to evaluate the combination of subcutaneous (sc) interleukin-2 (il-2) with interferon alpha-2a (ifn-alpha) in the treatment of patients with metastatic renal cell carcinoma (mrcc) compared with a previous trial that used continuous-infusion il-2 a